The notices it replaced
Its page names no earlier notice: it is new, or it does not say.
Replaced by PAR-18-761.
Who won it before
19 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,931,064 in first-year total cost, median $369,304.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]11
- Neurological Sciences and Disorders B Study Section[NSD-B]7
- Neurological Sciences and Disorders C Study Section[NSD-C]1
Most frequent institutions
- EMORY UNIVERSITY2
- OREGON HEALTH & SCIENCE UNIVERSITY2
- UNIVERSITY OF MIAMI SCHOOL OF MEDICINE2
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH2
- INDIANA UNIVERSITY INDIANAPOLIS1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Development and validation of small molecules to treat neurofibromatosis associated schwannoma1R21NS105941-01 | BANNISTER, THOMAS DKISSIL, JOSEPH | SCRIPPS FLORIDA, FL | $475,000 | NSD |
| 2018 | EP2 antagonists as novel anti-epileptogenic agents1R21NS101167-01A1 | GANESH, THOTA | EMORY UNIVERSITY, GA | $403,718 | NSD |
| 2018 | Use of CRISPR/Cas9 to treat Huntington disease1R21NS106120-01 | WARREN, STEPHEN T. | EMORY UNIVERSITY, GA | $390,000 | NSD |
| 2018 | DMF for intracerebral hemorrhage1R21NS104460-01 | ARONOWSKI, JAROSLAWSAVITZ, SEAN I | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $385,000 | NSD |
| 2018 | Reversal of preexisting neuropathic pain by spinal delivery of AIBP1R21NS104769-01A1 | MILLER, YURYYAKSH, TONY L. | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $380,298 | NSD |
| 2018 | 20-HETE Formation Inhibitors in Cardiac Arrest1R21NS107785-01 | MCDERMOTT, LEE APOLOYAC, SAMUEL M | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $369,304 | NSD |
| 2018 | Pharmacodynamics and in vivo efficacy of fumarate for mitochondrial disease in vivo1R21NS106719-01A1 | CORTOPASSI, GINO A | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $367,706 | NSD |
| 2018 | Exploring Antisense Oligonucleotides as a potential therapy for Autosomal Dominant Leukodystrophy1R21NS104384-01A1 | PADIATH, QUASAR S | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $353,208 | NSD |
| 2018 | Long Acting Local Analgesics: HSV-CA8 Biotherapeutics1R21NS105880-01 | LEVITT, ROY C. | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $329,297 | NSD |
| 2018 | Gene Therapy Knockdown and Replacement of GARS to Treat Dominant Inherited Peripheral Neuropathy1R21NS105116-01A1 | BURGESS, ROBERT W.HARPER, SCOTT Q | JACKSON LABORATORY, ME | $290,309 | NSD |
| 2017 | In vivo efficacy studies to support the development of DUX4-targeted RNAi therapy for FSHD1R21NS101166-01 | HARPER, SCOTT Q | RESEARCH INST NATIONWIDE CHILDREN'S HOSP, OH | $389,002 | NSD |
| 2017 | Neural Stem Cell Carriers for Glioblastoma Immunotherapy1R21NS101150-01 | BALYASNIKOVA, IRINA V | NORTHWESTERN UNIVERSITY AT CHICAGO, IL | $388,890 | NSD |
| 2017 | Complement inhibitors targeted to the ischemic brain for the treatment of stroke1R21NS097653-01A1 | TOMLINSON, STEPHEN | MEDICAL UNIVERSITY OF SOUTH CAROLINA, SC | $345,320 | NSD |
| 2016 | Global RNA Interference Therapy for Huntingtons Disease1R21NS095245-01A1 | MCBRIDE, JODI L. | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $437,500 | NSD |
| 2016 | Optimization of Compounds that Stabilize the SMN Protein for Treatment of SMA1R21NS095139-01 | ANDROPHY, ELLIOT J.HODGETTS, KEVINLORSON, CHRISTIAN L. | INDIANA UNIVERSITY INDIANAPOLIS, IN | $431,954 | NSD |
| 2016 | Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors1R21NS097643-01 | WEST, ANDREW B | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $367,500 | NSD |
| 2016 | Red blood cell microparticles (RMPs) to reduce bleeding following hemorrhagic stroke1R21NS094896-01 | DAVE, KUNJAN R | UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FL | $307,000 | NSD |
| 2016 | Modified neural stem cells for glycosylation-independent treatment of MPS IIIB1R21NS096044-01 | IACOVINO, MICHELINA | LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER, CA | $260,587 | NSD |
| 2016 | Development of Poly ICLC for neuroprotection against ischemic brain injury1R21NS094833-01A1 | STENZEL-POORE, MARY P | OREGON HEALTH & SCIENCE UNIVERSITY, OR | $259,471 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.